Previous close | 213.37 |
Open | 213.97 |
Bid | 210.75 x 800 |
Ask | 220.31 x 800 |
Day's range | 212.86 - 215.85 |
52-week range | 200.32 - 263.13 |
Volume | |
Avg. volume | 572,929 |
Market cap | 19.102B |
Beta (5Y monthly) | 1.04 |
PE ratio (TTM) | 19.39 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.35%) |
Ex-dividend date | 17 May 2023 |
1y target est | N/A |
Let's talk about the popular Laboratory Corporation of America Holdings ( NYSE:LH ). The company's shares saw...
NextEra Energy (NYSE: NEE) is a company well worth knowing about and adding to your watch list. The company bills itself as the world's largest utility company, and it can claim that in large part due to its ownership of the Florida Power & Light Company, which is itself "America's largest electric utility that sells more power than any other utility ..." There's a lot to like, or love, about NextEra Energy.
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.
Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
Laboratory Corporation of America Holdings ( NYSE:LH ) is about to trade ex-dividend in the next 4 days. The...
Laboratory Corporation of America Holdings ( NYSE:LH ) will pay a dividend of $0.72 on the 8th of June. This payment...
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
Key Insights The projected fair value for Laboratory Corporation of America Holdings is US$387 based on 2 Stage Free...
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
While the top- and bottom-line numbers for LabCorp (LH) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
LabCorp (LH) delivered earnings and revenue surprises of -4.26% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ongoing sales rebound in the base business for both Diagnostics and Drug Development segments is likely to have benefited LabCorp (LH) in Q1.
The board of Laboratory Corporation of America Holdings ( NYSE:LH ) has announced that it will pay a dividend of $0.72...
LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, autoimmune and liver disease as well as cell and gene therapy.
Today's Research Daily features new research reports on 16 major stocks, including TotalEnergies SE (TTE), America Movil, S.A.B. de C.V. (AMX) and Palo Alto Networks, Inc. (PANW).
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
Laboratory Corporation of America Holdings ( NYSE:LH ) Full Year 2022 Results Key Financial Results Revenue: US$14.9b...
Laboratory Corporation of America Holdings ( NYSE:LH ) stock is about to trade ex-dividend in 4 days. The ex-dividend...
The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.
LabCorp (LH) delivered earnings and revenue surprises of 1.97% and 2.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?